Introduction: Extremes of fetal growth are associated with increased perinatal mortality and morbidity and a higher prevalence of cardiovascular disease, obesity and diabetes in later life. We aimed to identify changes in placental gene expression in pregnancies with evidence of growth dysfunction and candidate genes that may be used to identify abnormal patterns of growth prior to delivery. Methods: Growth-restricted (n = 4), macrosomic (n = 6) and normal term (n = 5) placentas were selected from a banked series (n = 200) collected immediately after caesarean section. RNA was extracted prior to microarray analysis using Affymetrix HG-U219 arrays to determine variation in gene expression. Genes of interest were confirmed using qRT-PCR. Results: 338 genes in the growth-restricted and 41 genes in the macrosomic group were identified to be significantly dysregulated (>2-fold change; p < 0.05). CPXM2 and CLDN1 were upregulated and TXNDC5 and LRP2 downregulated in fetal growth restriction. In macrosomia, PHLDB2 and CLDN1 were upregulated and LEP and GCH1 were downregulated. Discussion: Dysfunctional growth is associated with differential placental gene expression and affects genes with a whole spectrum of developmental and cellular functions. Better elucidation of these pathways may allow the development of biomarkers to identify growth abnormalities and effective prenatal intervention.

Keywords:
Fetal growth restriction, Macrosomia, Development, Microarrays, Candidate genes
1.
Diplas AI, et al: Differential expression of imprinted genes in normal and IUGR human placentas. Epigenetics 2009;4:235-240.
2.
Figueras F, et al: Customised birth weight standards accurately predict perinatal morbidity. Arch Dis Child Fetal Neonatal Ed 2007;92:F277-F280.
3.
Edwards CA, Ferguson-Smith AC: Mechanisms regulating imprinted genes in clusters. Curr Opin Cell Biol 2007;19:281-289.
4.
Barker DJP: The developmental origins of adult disease. J Am Coll Nutr 2004;23(suppl 6):588S-595S.
5.
Das UG, Sysyn GD: Abnormal fetal growth: intrauterine growth retardation, small for gestational age, large for gestational age. Pediatr Clin North Am 2004;51:639-654, viii.
6.
Langer O: Fetal macrosomia: etiologic factors. Clin Obstet Gynecol 2000;43:283-297.
7.
Gu S, et al: Risk factors and long-term health consequences of macrosomia: a prospective study in Jiangsu Province, China. J Biomed Res 2012;26:235-240.
8.
Hermann GM, et al: Neonatal macrosomia is an independent risk factor for adult metabolic syndrome. Neonatology 2010;98:238-244.
9.
Jansson T, Powell TL: Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci 2007;113:1-13.
10.
Sibley CP, et al: Adaptation in placental nutrient supply to meet fetal growth demand: implications for programming. Placenta 2010;31(suppl):S70-S74.
11.
Bishry GE, Sturgiss SN: Absent end-diastolic flow velocity in the umbilical artery. Fetal Matern Med Rev 2003;14:251-271.
12.
Murphy VE, et al: Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr Rev 2006;27:141-169.
13.
Newbern D, Freemark M: Placental hormones and the control of maternal metabolism and fetal growth. Curr Opin Endocrinol Diabetes Obes 2011;18:409-416.
14.
Beeby PJ, Bhutap T, Taylor LK: New South Wales population-based birth weight percentile charts. J Paediatr Child Health 1996;32:512-518.
15.
American College of Obestetricians and Gynecologists: ACOG Practice Bulletin No 134: fetal growth restriction. Obstet Gynecol 2013;121:1122-1133.
16.
Sacks DA: Etiology, detection, and management of fetal macrosomia in pregnancies complicated by diabetes mellitus. Clin Obstet Gynecol 2007;50:980-989.
17.
Bolstad BM, et al: A comparison of normalization methods for high-density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193.
18.
Mi H, Thomas P: PANTHER pathway: an ontology-based pathway database coupled with data analysis tools; in Nikolsky Y, Bryant J (eds): Protein Networks and Pathway Analysis. New York, Humana Press, 2009, pp 123-140.
19.
Mi H, et al: PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res 2010;38(suppl 1):D204-D210.
20.
Nishizawa H, et al: Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol 2011;9:107-107.
21.
Toft JH, et al: Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med 2008;21:267-273.
22.
Sitras V, et al: Placental gene expression profile in intrauterine growth restriction due to placental insufficiency. Reprod Sci 2009;16:701-711.
23.
Lee MH, et al: Placental gene expression is related to glucose metabolism and fetal cord blood levels of insulin and insulin-like growth factors in intrauterine growth restriction. Early Hum Dev 2010;86:45-50.
24.
Dunk CE, et al: A distinct microvascular endothelial gene expression profile in severe IUGR placentas. Placenta 2012;33:285-293.
25.
Winn VD, et al: Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology 2009;150:452-462.
26.
Gasperowicz M, Otto F: The Notch signalling pathway in the development of the mouse placenta. Placenta 2008;29:651-659.
27.
Wit JM, Walenkamp MJ: Role of Insulin-Like Growth Factors in Growth, Development and Feeding. World Rev Nutr Diet. Basel, Karger, 2013, vol 106, pp 60-65.
28.
Zeggini E, et al: Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40:638-645.
29.
Considine RV, et al: Serum-immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
30.
Shekhawat PS, et al: Neonatal cord blood leptin: its relationship to birth weight, body mass index, maternal diabetes, and steroids. Pediatr Res 1998;43:338-343.
31.
Zhang Y, et al: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
32.
Kageyama H, et al: Neuronal circuits involving neuropeptide Y in hypothalamic arcuate nucleus-mediated feeding regulation. Neuropeptides 2012;46:285-289.
33.
Valuniene M, et al: Leptin levels at birth and in early postnatal life in small- and appropriate-for-gestational-age infants. Medicina (Kaunas) 2007;43:784-791.
34.
Martinez-Cordero C, et al: Body fat at birth and cord blood levels of insulin, adiponectin, leptin, and insulin-like growth factor-I in small-for-gestational-age infants. Arch Med Res 2006;37:490-494.
35.
Weyermann M, et al: Adiponectin and leptin in maternal serum, cord blood, and breast milk. Clin Chem 2006;52:2095-2102.
36.
Grisaru-Granovsky S, et al: Maternal and umbilical cord serum leptin concentrations in small-for-gestational-age and in appropriate-for-gestational-age neonates: a maternal, fetal, or placental contribution? Biol Neonate 2003;84:67-72.
37.
Pighetti M, et al: Maternal serum and umbilical cord blood leptin concentrations with fetal growth restriction. Obstet Gynecol 2003;102:535-543.
38.
Yildiz L, Avci B, Ingec M: Umbilical cord and maternal blood leptin concentrations in intrauterine growth retardation. Clin Chem Lab Med 2002;40:1114-1117.
39.
Varvarigou A, Mantzoros V, Beratis NG: Cord blood leptin concentrations in relation to intrauterine growth. Clin Endocrinol (Oxf) 1999;50:177-183.
40.
Koistinen HA, et al: Leptin concentration in cord blood correlates with intrauterine growth. J Clin Endocrinol Metab 1997;82:3328-3330.
41.
Ategbo JM, et al: Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab 2006;91:4137-4143.
42.
Mazaki-Tovi S, et al: Cord blood adiponectin in large-for-gestational age newborns. Am J Obstet Gynecol 2005;193:1238-1242.
43.
Yang SW, Kim SY: The relationship of the levels of leptin, insulin-like growth factor-I and insulin in cord blood with birth size, ponderal index, and gender difference. J Pediatr Endocrinol Metab 2000;13:289-296.
44.
D'Souza AM, et al: Leptin deficiency in rats results in hyperinsulinemia and impaired glucose homeostasis. Endocrinology 2014, Epub ahead of print.
45.
Leach L, et al: Vasculogenesis, angiogenesis and the molecular organisation of endothelial junctions in the early human placenta. J Vasc Res 2002;39:246-259.
46.
Pirinen E, Soini Y: A survey of zeb1, twist and claudin-1 and -4 expression during placental development and disease. APMIS 2013, Epub ahead of print.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.